Marvel Biosciences Corp. (MRVL.V)
CAD 0.16
(10.34%)
CAD 0.16
(10.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.29 Million CAD | 10.29% |
| 2022 | -2.55 Million CAD | 15.96% |
| 2021 | -3.03 Million CAD | -218.04% |
| 2020 | -955.65 Thousand CAD | -874.72% |
| 2019 | -98.04 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -307.31 Thousand CAD | -32.0% |
| 2024 Q2 | -232.81 Thousand CAD | 55.08% |
| 2024 Q1 | -518.29 Thousand CAD | 50.44% |
| 2023 Q2 | -232.99 Thousand CAD | 21.34% |
| 2023 FY | -2.29 Million CAD | 10.29% |
| 2023 Q3 | -716.32 Thousand CAD | -207.45% |
| 2023 Q4 | -1.04 Million CAD | -46.0% |
| 2023 Q1 | -296.2 Thousand CAD | 49.1% |
| 2022 Q1 | -510.21 Thousand CAD | 75.56% |
| 2022 FY | -2.55 Million CAD | 15.96% |
| 2022 Q4 | -581.88 Thousand CAD | -48.34% |
| 2022 Q2 | -1.06 Million CAD | -109.67% |
| 2022 Q3 | -392.27 Thousand CAD | 63.33% |
| 2021 Q2 | -167.65 Thousand CAD | 53.74% |
| 2021 Q1 | -362.39 Thousand CAD | 0.0% |
| 2021 FY | -3.03 Million CAD | -218.04% |
| 2021 Q3 | -421.83 Thousand CAD | -151.6% |
| 2021 Q4 | -2.08 Million CAD | -394.85% |
| 2020 FY | -955.65 Thousand CAD | -874.72% |
| 2019 FY | -98.04 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | 31.122% |
| Covalon Technologies Ltd. | -4.46 Million CAD | 48.635% |
| Hemostemix Inc. | -2.5 Million CAD | 8.422% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 78.169% |
| Kane Biotech Inc. | -5.03 Million CAD | 54.483% |
| MedMira Inc. | -2.67 Million CAD | 14.362% |
| NervGen Pharma Corp. | -22.38 Million CAD | 89.762% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | 19.864% |